Sodium Citrate for Health & Longevity - Quick Reference Sheet

Sodium Citrate for Health & Longevity

Created on 08/27/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Sodium citrate is a salt the body converts into base, making blood and urine less acidic. Where that is the actual problem — acid build-up from failing kidneys, urine too acidic to keep uric acid dissolved, kidney stones — the measured effects are real. Each unit of citrate arrives with three of sodium, nudging blood pressure upward. Stomach upset is common. (Full Review)

Protocol

Standard alkalinizing dose
30–60 mEq/day
The oral solution provides 1 mEq per mL, so 30–60 mL daily.
Ergogenic dose
0.4–0.5 g/kg
Roughly ten times the daily alkalinizing dose; not run chronically.
Single versus split dosing
Split 2–3× daily
Split after meals and at bedtime for tolerance and steadier urinary citrate; ergogenic use needs a single bolus.
Time to effect
Kidney & stone endpoints
6 months – several years
The outcome endpoints, and the slowest to move.
Urinary citrate & pH
24–48 hours
Reverts to baseline about 48 hours after the last dose.
Blood bicarbonate
120–180 minutes
Sets the pre-exercise interval, individualised rather than fixed at 90 minutes.

Benefits

Contraindications
  • Concurrent aluminium antacid or phosphate binder
  • Heart failure NYHA Class III or IV, or decompensated
  • Cirrhosis with ascites, or Child-Pugh Class C
  • eGFR below 30 mL/min/1.73 m² outside nephrology care
  • Pre-existing metabolic alkalosis, serum bicarbonate above 30 mEq/L, or untreated hypokalemia below 3.5 mmol/L
  • Active calcium phosphate stone disease, or persistent urine pH above 6.8
  • Uncontrolled hypertension above 160/100 mmHg, and salt-sensitive hypertension generally
  • Adrenal insufficiency or aldosterone excess
Key Interactions
  • Potassium-sparing diuretics (spironolactone, amiloride) and renin-angiotensin blockers (lisinopril, losartan)
  • Lithium
  • Weak-base drugs cleared renally (amphetamines, memantine, quinidine, flecainide)
  • Weak-acid drugs (salicylates, methotrexate)
  • Thiazide and loop diuretics (hydrochlorothiazide, furosemide)
  • Over-the-counter antacids and effervescent analgesics
  • Additive alkali supplements (sodium bicarbonate, potassium citrate, calcium citrate, magnesium citrate)
  • Blood-pressure-lowering supplements (beetroot nitrate, potassium, magnesium, garlic, omega-3)
  • High-protein and ketogenic diets, sodium restriction protocols, DASH-style eating

Risk & Side Effects

  • High: Gastrointestinal distress; sodium loading and rise in blood pressure
  • Medium: Iatrogenic metabolic alkalosis; increased calcium phosphate and sodium urate supersaturation
  • Low: Fluid retention and volume overload; enhanced intestinal aluminium absorption
  • Speculative: Citrate-induced hypocalcaemia; dental enamel erosion from effervescent preparations

Monitoring

Marker Target Why
Serum bicarbonate (CO₂) 24–26 mEq/L Confirms acidosis corrected without overshoot
Serum sodium 137–142 mmol/L Detects sodium loading and hypernatremia
Serum potassium 4.0–4.5 mmol/L Alkalosis shifts potassium into cells
Home blood pressure (7-day average) Below 120/80 mmHg The primary sodium-load endpoint
eGFR Above 90 mL/min/1.73 m²; otherwise own slope The endpoint alkali therapy targets in kidney disease
24-hour urine citrate Above 640 mg/day, target 800–1,000 mg/day on therapy The direct measure of whether the dose is working
24-hour urine pH 6.0–6.5 Above 6.0 dissolves uric acid; above 6.8 precipitates calcium phosphate
24-hour urine calcium Below 200 mg/day Sodium citrate does not lower it, unlike the potassium salt
24-hour urine sodium Below 100 mmol/day The objective check on total sodium intake
Serum ionised calcium 1.16–1.30 mmol/L Citrate chelates calcium; alkalosis lowers the ionised fraction
Serum uric acid 3.5–5.5 mg/dL Sets the target urine pH for uric acid stone formers

Cadence: Serum electrolytes and bicarbonate at four weeks and again at twelve weeks after any dose change; home blood pressure weekly through the first three months; urine pH by home strip twice weekly during titration; full 24-hour urine collection at three months and thereafter every six to twelve months.

Qualitative Assessment

  • Stool form and frequency, and any bloating or cramping in the two hours after a dose
  • Ankle or finger swelling, ring or shoe tightness, and unexplained short-term weight gain
  • Breathlessness on exertion or when lying flat, which would suggest fluid retention
  • Tingling around the mouth or in the fingers, or muscle twitching, suggesting overshoot into alkalosis
  • Flank discomfort, visible blood in urine, or gravel passage indicating stone activity
  • Perceived exertion and late-effort fatigue during high-intensity training sessions
  • Burning or urgency on urination, and how quickly it settles after a dose